Cefaclor solutions in pH 2.5 and 4.5 buffers contained at least 90% of their initial activity after 72 h at 40C. Samples in pH 6.0, 7.0, and 8.0 buffers contained 70, 46, and 34%, respectively, of their initial activity after 72 h at 4C. After 72 h at 250C, samples prepared with pH 2.5, 4.5, 6.0, 7.0, and 8.0 buffers contained 95, 69, 16, 5, and 3%, respectively, of their initial activity. After 72 h at 370C, cefaclor solutions in pH 2.5 buffer contained 80% of the initial activity, whereas samples prepared in pH 4.5, 6.0, 7.0, and 8.0 buffers contained less than 20%. Laboratory-prepared plasma and serum samples showed an 8% loss in activity when incubated for 6 h at 40C, a 51% loss when incubated for 6 h at 250C, and a 48% loss when incubated for 2 h at 370C. Clinical samples demonstrated a similar stability pattern. Degradation rates for cefaclor in commercially prepared serum increased from 4-to 10-fold in comparison to rates obtained when samples were made in human serum freshly prepared in our laboratory. Consequently, serum standards should be made in freshly prepared human serum.
Cefaclor, 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid, is an orally effective, broad-spectrum cephalosporin derivative that has been shown by Sullivan et al. (3) to be quantitatively absorbed as the intact antibiotic from the gastrointestinal tract of mice, rats, and dogs. Cefaclor is structurally related to other cephalosporins, in particular cephalexin, but possesses stability characteristics different from those of cephalexin. This study describes the stability characteristics of cefaclor and outlines procedures for the proper handling and evaluation of clinical samples.
MATERIALS AND METHODS
Stability of cefaclor in buffer. The stability of cefaclor in the following 0.1 M potassium phosphate buffers was examined: pH 2.5, 4.5, 6.0, 7.5, and 8.0. Samples were prepared at 1 mg of cefaclor activity per ml in the appropriate buffer and incubated at 37, 25, and 40C. Samples were assayed at 0-, 24-, 48-, and 72-h intervals by removing an appropriate amount of the sample, diluting it 100-fold with 0.1 M pH 4.5 potassium phosphate buffer, and assaying by the AUTOTURB System (2) against a standard curve prepared in 0.1 M pH 4.5 potassium phosphate buffer at concentrations of 2.0, 5.0, 10.0, 20.0, and 40.0 itg of cefaclor activity per ml. Staphylococcus aureus ATCC 9144 was used as the test organism.
In vitro stability of cefaclor in plasma and serum. Samples were prepared at 10 Zg of cefaclor activity per ml in either pooled human serum obtained commercially or serum and plasma obtained from the same healthy volunteers. The fluids were tested before use to ensure that they were devoid of antimicrobial activity. The pH was adjusted to 7.45 by the addition of 2 N HCl. Samples were incubated at 4, 25, and 3700, and the pH was maintained at 7.45 by overlaying the sample with an atmosphere of 95% 02-5% C02. A 1-ml sample was removed at appropriate intervals up to 6 h, diluted 100-fold with pH 4.5 buffer, stored at 40C, and assayed immediately after the 6-h sample was drawn. After each sampling period, the reaction vessel was flushed for 2 min with the 95% 02-5% C02 gas mixture.
Samples were assayed by a modification of the microbiological agar diffusion assay described by Kavanagh and Dennin (1). Plastic petri plates (100 by 15 mm) contained a 10-ml layer of Antibiotic Medium no. 1 (Difco). The agar was seeded with a 0.2-ml suspension of a 1:10 dilution ofSarcina lutea ATCC 9341 (adjusted to a 30% light transmission at 530 nm with a Spectronic 20 spectrophotometer) for each 100 ml of agar. Standards for the assay were derived by volumetric dilution from a freshly prepared pH 4.5 buffer stock solution containing 1,000 ,Ag of cefaclor activity per ml. Intermediate and final dilutions were made in pH 4.5 buffer containing 1% human serum or plasma. Standards containing 0.025, 0.05, 0.1, or 0.2 Ag of cefaclor activity per ml were applied at a dosage of 0.1 ml/cylinder. Plates were incubated at 30°C for 16 to 18 h, and zones of inhibition were read to the pearest 0.1 mm with a Fisher-Lilly antibiotic zone reader.
Effect of sample handling on blood concentrations. In an attempt to relate the stability observed in laboratory-prepared samples to the handling of 50 FOGLESONG, LAMB, AND DIETZ clinical blood samples, 500 mg of cefaclor was given to a healthy volunteer and blood samples were collected at time intervals of 0, 10, 20, 30, 45, 60, 90, 120, and 180 min after the administration of the drug. Samples were collected in heparinized tubes and immediately centrifuged in a refrigerated centrifuge (4°C) at 1,000 x g for 10 min to separate the plasma from cellular fractions. Each sample was then divided, and one part was held at 4°C and the other part was held at 25°C for 4 h before assay.
Samples were assayed by a disk plate agar diffusion procedure. Plastic petri plates (150 by 15 mm) contained a 45-ml layer of Antibiotic Medium no. 1 inoculated with S. lutea ATCC 9341 as described earlier. Standards for the tests were prepared by volumetric dilution from a freshly prepared pH 4.5 buffer stock solution containing 1,000 itg of cefaclor activity per ml. The standards were diluted in control human plasma to contain 0.16, 0.63, 2.5, 10.0, and 20.0 ,ug of cefaclor activity per ml. The standard solutions were applied to each disk (6.35-mm, a-cellulose disk, BBL) by dipping the disk in the standard solution until fully saturated. Plates were incubated and zone diameters were read as described earlier.
RESULTS
Temperature and pH stability. After storage for 72 h at 40C, cefaclor solutions in pH 2.5 buffer contained 95% of their initial activity, in pH 4.5 buffer contained 93%, in pH 6.0 buffer contained 71%, in pH 7.0 buffer contained 46%, and in pH 8.0 buffer contained 34% (Fig. 1A) . Loss of activity was accelerated by storage at250C (Fig. 1B) A dramatically different stability pattern was observed when cefaclor was added to commercially prepared pooled human serum. The loss of activity as the percentage of the initial activity at 4, 25, and 370C is shown in Fig. 3A .
Losses of approximately 15% per h at 40C, 45% per h at 250C, and 68% per h at 37C were observed.
Effect of sample handling on apparent blood concentrations. In view of the effect that temperature and pH had on the stability of laboratory-prepared samples of cefaclor, the effects of storage temperature on the recovery of cefaclor from clinical blood samples were examined. As As would be predicted from the pH buffer stability data, cefaclor was unstable in vitro in human serum and plasma. Over 50% of the initial antimicrobial activity was lost when prepared serum and plasma samples were held at 250C for 6 h (Fig. 2) . Conversely, only 5 to 10% of the activity was lost when the same samples were held at 4°C for the same time period (Fig. 2) . At 37°C, the degradation was even greater, and approximately 50% of the initial activity was lost in 2 h.
Similarly, clinical samples stored at room 
